Compare TR & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TR | TLX |
|---|---|---|
| Founded | 1896 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.3B |
| IPO Year | 1994 | 2024 |
| Metric | TR | TLX |
|---|---|---|
| Price | $38.64 | $9.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.09 |
| AVG Volume (30 Days) | 161.9K | ★ 323.3K |
| Earning Date | 10-21-2026 | 10-22-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 12.30 | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $16.59 |
| Revenue Next Year | N/A | $13.64 |
| P/E Ratio | ★ $54.26 | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.95 | $6.28 |
| 52 Week High | $45.06 | $13.11 |
| Indicator | TR | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 56.45 | 46.78 |
| Support Level | $36.80 | $8.69 |
| Resistance Level | $39.48 | $11.37 |
| Average True Range (ATR) | 1.10 | 0.22 |
| MACD | 0.31 | 0.09 |
| Stochastic Oscillator | 77.22 | 76.19 |
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.